Global Hemophilia Market: Size, Trends & Forecast with Impact of COVID-19 (2022-2026)

Global Hemophilia Market: Size, Trends & Forecast with Impact of COVID-19 (2022-2026)Scope of the Report

The report titled “Global Hemophilia Market: Size, Trends & Forecast with Impact of COVID-19 (2022-2026)”, provides an in-depth analysis of global hemophilia market by value, by number of identified patient, by severity, by therapy type, by region (North America (The US and rest of the North America), Europe, Asia Pacific, and Rest of the World), etc. The report also provides a detailed analysis of the COVID-19 impact on global hemophilia market.

The report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of global hemophilia market has also been forecasted for the period 2022-2026, taking into consideration the previous growth patterns, the growth drivers, and the current and future trends.

The global hemophilia market is highly competitive. The key players of global hemophilia market are CSL Ltd. (CSL Behring), Pfizer Inc., Bayer Group, and BioMarin Pharmaceutical Inc. are also profiled with their financial information and respective business strategies.

Company Coverage

CSL Ltd. (CSL Behring)
Pfizer Inc.
Bayer Group
BioMarin Pharmaceutical Inc.

Regional Coverage

North America
Europe
Asia Pacific
Rest of the World

Executive Summary

Hemophilia is usually an inherited bleeding disorder in which the blood does not clot properly. This can lead to spontaneous bleeding as well as bleeding following injuries or surgery. Blood contains many proteins called clotting factors that can help to stop bleeding. People with hemophilia have low levels of either factor VIII (8) or factor IX (9). The severity of hemophilia that a person has is determined by the number of factors in the blood. The lower the amount of the factor, the more likely it is that bleeding will occur which can lead to serious health problems.

The global hemophilia market can be segmented based on Disease Type (Hemophilia A, Hemophilia B, and Unknown Type); Severity (Mild, Moderate, Severe, and Unknown); and Therapy Type (Replacement Therapy, Immune Tolerance Induction (ITI) Therapy, and Gene Therapy).

During the pandemic, the global hemophilia market grew. As per guidelines of vaccine for patients with severe/moderate hemophilia, the vaccine injection should be given after a factor VIII (FVIII) or factor IX (FIX) injection. As a result of the increased prevalence of coronavirus, demand for hemophilia therapies and medications to reduce the risk of COVID-19 increased. This has further contributed to the positive growth trajectory of the market.

The global hemophilia market has increased during the years 2017-2021. The projections are made that the market would rise in the next four years i.e. 2022-2026 tremendously. The global hemophilia market is expected to increase due to the rising incidence of a bleeding disorder, increasing healthcare spending, rising male population, increased focus on prophylactic treatment, favorable initiatives and policies, increasing investment in R&D and new product development, etc. Yet the market faces some challenges such as high cost of treatment, shortage of specialists, reluctance to switch to new therapies, etc. Moreover, the market growth would succeed by various market trends like increasing innovation in gene therapy, development of novel hemophilia treatments, shifting focus to extended half-life therapies, etc.